Press Releases

Date Headline
1/15/2022
Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual Rule
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Jan. 15, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the “NYSE  Continue Reading
1/6/2022
Zymeworks to Present at 40th Annual J.P. Morgan Healthcare Conference
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Jan. 6, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Neil Klompas , Zymeworks’ Chief Operating Officer and Chief Financial Officer, will  Continue Reading
1/5/2022
Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani
 Summary
Co-founder Dr. Ali Tehrani to remain as an advisor to the Company to assist in the transition expected to occur on or before February 1, 2022 Chief Financial Officer (CFO) Neil Klompas also promoted to the dual position of Chief Operating Officer (COO) and CFO effective immediately VANCOUVER,  Continue Reading
Displaying 21 - 23 of 23
Copyright 2022 , Zymeworks Inc.